Takeda Ventures

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

PSI provides life-saving information, products, and services to tackle some of the world’s most pressing health problems so that people can lead healthier, happier, and more productive lives.

Ascentage Pharma is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers, hepatitis B virus (HBV), and age-related diseases. Its pipeline comprises seven drug candidates targeting protein-protein interactions and tyrosine kinases.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Larkspur Biosciences specializes in developing precision immunotherapies for specific patient groups with molecularly defined cancers. Its focus is on targeting the interaction between tumors and the immune system to stimulate robust, long-lasting responses.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Nimbus Lakshmi operates as a wholly-owned subsidiary of Nimbus Therapeutics and offers tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858, an orally administered, selective allosteric inhibitor of TYK2, is currently undergoing assessment for its potential in treating various autoimmune diseases, following promising Phase 2b outcomes in psoriasis.

Zelluna Immunotherapy is a Norwegian biopharmaceutical company focused on developing T-cell receptor based cancer immunotherapies. Founded in 2016 and based in Oslo, it pursues a pipeline of tumor-specific TCRs, many derived from patients who showed long-term survival after peptide-based cancer vaccine trials at the Norwegian Radium Hospital/Oslo University Hospital. The company aims to enable immune cells to recognize a broad range of cancers with safety and durability. It operates in collaboration with Oslo Cancer Cluster and is located at the Oslo Cancer Cluster Innovation Park near major hospital facilities and GMP-certified cellular therapy capabilities.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Founded in 2020, Egle Therapeutics is a biotechnology company based in Paris, France. It specializes in developing immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

XFOREST Therapeutics specializes in developing RNA-targeted small molecule therapeutics for diseases previously considered undruggable. The company employs a structure-based discovery platform that combines high-throughput RNA motif screening and splicing modulation analysis, enabling the identification of selective binders to accelerate drug development in areas such as oncology, neuroscience, immunology, and rare diseases.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

PVP Biologics, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapeutic products for celiac disease. Established in 2015, the company specializes in creating an oral enzyme designed to break down immuno-reactive components of gluten in the stomach. This approach aims to alleviate the painful symptoms and intestinal damage caused by accidental gluten ingestion in individuals with celiac disease. By advancing this product candidate, PVP Biologics seeks to significantly reduce the burden of living with this condition and improve the quality of life for those affected. As of early 2020, PVP Biologics operates as a subsidiary of Takeda Pharmaceutical Company Limited.

Emendo Biotherapeutics is a biotechnology company focused on advancing genome editing technologies to develop genetic medicines. Established by a team of experts with backgrounds in protein engineering and DNA repair from prestigious institutions, Emendo aims to tackle the challenges associated with gene therapy. By innovating and transforming existing tools, the company seeks to address diseases and disorders that are presently deemed untreatable. Emendo's approach fuses diverse scientific disciplines with creative problem-solving, enabling the development of advanced gene editing solutions that enhance the efficacy of gene therapy and expand its potential applications. Through this commitment to pushing the boundaries of science, Emendo Biotherapeutics strives to fulfill the promise of gene editing for improved patient outcomes.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR, targeting neurodegenerative and neuroinflammatory diseases. The company utilizes unique computational methods to develop a series of novel and selective molecules, which are validated through clinically relevant assays. This approach aims to address issues such as memory consolidation impairment and enhance long-term memory in patients. In 2019, ProteKt Therapeutics graduated from the FutuRx accelerator and subsequently raised $4 million in a pre-A funding round to support its innovative research and development efforts.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Axcelead specializes in early-stage drug discovery services. It offers integrated solutions, combining scientific expertise, robust intellectual property protection, and state-of-the-art facilities to support clients from exploratory research to optimizing candidate compounds.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Bsense Bio Therapeutics develops small-molecule therapeutics for sensory hyperexcitability-related disorders. It pursues a novel approach that targets multiple hyperexcitability mechanisms with a single compound, focusing on two cation channels: a ligand-gated cation channel and a voltage-gated potassium channel, to improve efficacy and safety.

Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.

GEXVal Inc. is a drug discovery company based in Fujisawa, Japan, founded in 2018. The company focuses on the research and development of innovative treatments for rare and incurable diseases, particularly in the fields of psychiatry, neurology, and pulmonary arterial hypertension. GEXVal is dedicated to addressing the needs of patients and families affected by these conditions by providing cost-effective treatment options that aim to enhance health and improve quality of life. Through its specialized research efforts, GEXVal seeks to develop compounds that target intractable diseases, enabling physicians to offer better therapeutic solutions to their patients.

ARTham Therapeutics Inc is a biopharmaceutical company based in Naka-Ku, Japan, founded in 2018. The company focuses on delivering innovative biological medicines aimed at treating debilitating diseases. Its portfolio includes programs such as art-648, art-ep, art-pde, and art-001, which are designed to address specific medical needs in areas including inflammatory skin diseases, vascular malformations, and immuno-oncology endometriosis. Operating under a virtual research and development model, ARTham Therapeutics collaborates with academic and business partners to drive innovation and create disease-modifying therapies that enhance patient health and quality of life.

Quince Therapeutics is a preclinical-stage biopharmaceutical company focused on developing precision therapeutics for debilitating and rare diseases. Its core technology is a bone-targeting drug platform designed to deliver small molecules, peptides, or large molecules directly to the site of bone fractures and diseases, promoting rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Shire is a global biopharmaceutical company focused on developing and marketing therapies for rare diseases. It maintains a broad portfolio across hematology, immunology, neuroscience, ophthalmology, internal medicine and endocrine disorders, and hereditary angioedema. The company operates a worldwide sales and marketing network with direct marketing in the United States, Canada, the United Kingdom, Ireland, France, Germany, Italy and Spain. It emphasizes patient-focused care and aims to deliver innovative therapies to patients with rare diseases worldwide.

Fimecs is a biotechnology company that specializes in drug discovery focused on protein degradation technology. The firm aims to develop first-in-class therapeutics targeting the degradation of proteins associated with cancers and other challenging diseases. Utilizing a proprietary platform based on ubiquitin E3 ligase binders, Fimecs designs small molecules that can induce the degradation of specific proteins, many of which are considered undruggable. This innovative approach targets proteins linked to various diseases, expanding the potential for effective treatment options beyond the traditionally druggable targets identified in small molecule drug discovery. Through its emphasis on targeted protein degradation, Fimecs is positioned to contribute significantly to the advancement of anti-cancer therapies and the treatment of other hard-to-treat conditions.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

SEEDSUPPLY is a research and development company based in Fujisawa, Kanagawa, Japan, that specializes in creating medical and agricultural chemical products. Established in May 2017 as a spin-off from Takeda Pharmaceutical Company Limited, SEEDSUPPLY operates a drug discovery platform focused on the development of small molecule drugs. The company utilizes binder selection technology to address drug targets that are typically difficult to analyze with conventional high-throughput screening methods. This innovative approach enables medical professionals to explore new possibilities in the discovery of drug candidate compounds, contributing to advancements in medical treatments.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

OrphoMed, Inc. is a San Francisco-based pharmaceutical company that specializes in developing novel therapies for conditions such as irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis. Established in 2015, the company utilizes its proprietary DIMERx™ platform technology to create first-in-class therapeutic dimer conjugates aimed at addressing visceral hypersensitivity and pancreatitis. Among its key pipeline candidates is ORP-101, a peripherally acting sodium ion channel blocker that acts as a μ agonist and κ antagonist, designed to minimize abuse potential and reduce risks associated with pancreatitis. OrphoMed is also working on ORP-105, a non-addictive, centrally-acting analgesic, and ORP-110, a potentiator for cystic fibrosis treatment. The company's innovative approach not only aims to reshape pain management but also seeks to fulfill unmet medical needs across various gastrointestinal and pain-related disorders, leveraging the safety and efficacy of its compounds, which have proven track records for other indications.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Quince Therapeutics is a preclinical-stage biopharmaceutical company focused on developing precision therapeutics for debilitating and rare diseases. Its core technology is a bone-targeting drug platform designed to deliver small molecules, peptides, or large molecules directly to the site of bone fractures and diseases, promoting rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Scohia Pharma is a Fujisawa, Japan-based biopharmaceutical company focused on researching, designing, and developing therapies for metabolic, cardiovascular, and renal diseases. Its work targets lifestyle-related conditions such as obesity, diabetes, dyslipidemia, and hypertension, with an emphasis on delivering treatments that improve patient outcomes through research and development across metabolic and renal disorders.

Ariad Pharmaceuticals, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of innovative cancer therapies. The company’s flagship product, Iclusig (ponatinib), is a tyrosine kinase inhibitor approved for the treatment of adult patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in multiple regions, including the United States and Europe. Additionally, Ariad is developing Brigatinib, an investigational treatment targeting anaplastic lymphoma kinase for non-small cell lung cancer, as well as AP32788, aimed at treating non-small cell lung cancer and other solid tumors. The company markets Iclusig through specialty pharmacies in the U.S. Established in 1991, Ariad Pharmaceuticals operates as a subsidiary of Takeda Pharmaceuticals U.S.A., Inc., and remains committed to advancing therapies that transform the lives of cancer patients.

PVP Biologics, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapeutic products for celiac disease. Established in 2015, the company specializes in creating an oral enzyme designed to break down immuno-reactive components of gluten in the stomach. This approach aims to alleviate the painful symptoms and intestinal damage caused by accidental gluten ingestion in individuals with celiac disease. By advancing this product candidate, PVP Biologics seeks to significantly reduce the burden of living with this condition and improve the quality of life for those affected. As of early 2020, PVP Biologics operates as a subsidiary of Takeda Pharmaceutical Company Limited.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Emendo Biotherapeutics is a biotechnology company focused on advancing genome editing technologies to develop genetic medicines. Established by a team of experts with backgrounds in protein engineering and DNA repair from prestigious institutions, Emendo aims to tackle the challenges associated with gene therapy. By innovating and transforming existing tools, the company seeks to address diseases and disorders that are presently deemed untreatable. Emendo's approach fuses diverse scientific disciplines with creative problem-solving, enabling the development of advanced gene editing solutions that enhance the efficacy of gene therapy and expand its potential applications. Through this commitment to pushing the boundaries of science, Emendo Biotherapeutics strives to fulfill the promise of gene editing for improved patient outcomes.

Bioniz Therapeutics, Inc. is a biopharmaceutical company based in Irvine, California, established in 2009. It specializes in discovering and developing innovative peptide therapeutics aimed at treating immune diseases and cancer. The company's pipeline includes BNZ-1, a selective inhibitor targeting interleukin cytokines IL2, IL9, and IL15, which are significant contributors to conditions such as HTLV-1 Associated Myelopathy and T-cell leukemias. Additionally, Bioniz is developing IL-15 and IL-21 inhibitors, as well as BNZ-3, an early-stage asset focused on inhibiting IL-4, IL-9, and IL-21 cytokines. Bioniz Therapeutics is committed to advancing its lead technologies through proof of concept and preclinical studies, with the goal of partnering for clinical trials and eventual commercialization.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, focusing on serious genetic conditions with limited treatment options. The company leverages its team's experience to create life-changing medicines by advancing underdeveloped scientific research in these areas.

Quince Therapeutics is a preclinical-stage biopharmaceutical company focused on developing precision therapeutics for debilitating and rare diseases. Its core technology is a bone-targeting drug platform designed to deliver small molecules, peptides, or large molecules directly to the site of bone fractures and diseases, promoting rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Aquinnah Pharmaceuticals, Inc., founded in 2014 and based in Cambridge, Massachusetts, is a pharmaceutical company dedicated to developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on innovative research aimed at modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its specialized approach, Aquinnah Pharmaceuticals aims to address critical unmet medical needs in the field of neurodegeneration.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. The company specializes in developing novel small-molecule antiviral therapeutics through its innovative drug discovery platform, which utilizes cell-free protein synthesizing systems. This platform enables the identification of small molecule drugs that may be overlooked by traditional pharmaceutical screening methods. Prosetta Biosciences is engaged in collaborative efforts with both commercial and non-profit partners to advance compounds targeting a variety of human diseases, including oncology, neurodegenerative disorders, and infectious diseases. The company's focus on modulating the assembly of multi-protein complexes within cells positions it as a significant player in the biopharmaceutical sector.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Encycle Therapeutics, Inc. is a biotechnology company based in Toronto, Canada, that focuses on developing innovative drug candidates using its proprietary platform technology for the rapid synthesis of drug-like macrocycles and membrane-permeable nacellins. These nacellins are designed to target challenging intracellular protein-protein interactions, offering a potential alternative to traditional small molecules and biologics, such as monoclonal antibodies. The company has established collaborations with various pharmaceutical firms to build a screening library of nacellins, many of which demonstrate cell-permeable and drug-like characteristics. Encycle is actively pursuing the independent development of nacellins aimed at specific targets, including integrin alpha-4-beta-7 for inflammatory bowel disease and SMURF2 for fibrosis. Its lead program seeks to create orally bioavailable inhibitors of integrin alpha-4-beta-7 that promise improved safety and reduced immunogenicity compared to existing biologics targeting this protein.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

ArmaGen, Inc. is a clinical-stage biotechnology company based in San Diego, California, specializing in the development of therapies for severe neurological diseases. The company focuses on lysosomal storage disorders and neurodegenerative diseases, including Hunter syndrome, Hurler syndrome, Sanfilippo A syndrome, and metachromatic leukodystrophy. ArmaGen's innovative product candidates, such as AGT-182 and AGT-181, are designed to penetrate the blood-brain barrier, allowing for more effective treatment of neurological complications associated with these conditions. Founded in 2001, ArmaGen aims to improve the quality of life for patients suffering from these challenging disorders through its targeted therapeutic approaches.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

LigoCyte Pharmaceuticals is a biotechnology company focused on developing innovative vaccines and therapeutic monoclonal antibodies aimed at treating inflammatory and infectious diseases. The company specializes in creating commercial vaccines and biodefense vaccines, with notable products including Norovirus VLP Vaccines, which mimic the live virus's surface configuration without causing infection, and an Influenza VLP Vaccine that offers protection against multiple strains, including A/H1N1 and A/H3N2. Additionally, LigoCyte is involved in the development of an anthrax vaccine and Anti-CD103 monoclonal antibodies, which play a role in the retention of activated lymphocytes at sites of inflammation. By advancing its proprietary products into human clinical testing, LigoCyte is positioned for growth in the biotechnology sector, contributing to the field of immunomodulatory drugs that target disease processes rather than merely alleviating symptoms.

Intellikine is a biopharmaceutical company focused on the discovery and development of innovative small molecule therapies that target the PI3K/Akt/mTOR signaling pathway. The company specializes in creating drugs designed to treat various conditions, including cancer, inflammation, and autoimmune disorders. Its product portfolio features several notable candidates, such as INK128, an orally-available inhibitor that targets TORC1/2 for solid tumor malignancies, and INK1197, a dual PI3K selective inhibitor aimed at treating immune-mediated inflammatory diseases like rheumatoid arthritis and asthma. Intellikine is dedicated to fostering a skilled team and a robust discovery platform to accelerate the development of kinase inhibitors that have the potential to lead to significant medical advancements.

Redwood Bioscience is a biotechnology company focused on precision protein-chemical engineering to develop optimized biotherapeutics. Established in 2008 and based in Emeryville, California, the company specializes in site-specific modification technology, which addresses the challenges of conjugating biologics with synthetic molecules. This innovative approach enables the creation of homogeneous hybrid biotherapeutics, enhancing the effectiveness of treatments. Redwood Bioscience's methods for optimizing drug conjugates leverage the binding specificity and extended half-life of biologic carriers while incorporating the potency advantages of small molecules and synthetic peptides, positioning the company at the forefront of advancements in antibody-drug conjugates and semi-synthetic biotherapeutics.

Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio. Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy. Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners. Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

Founded in 2001, Domainex Ltd. is a UK-based biotechnology company specializing in contract research and manufacturing services for drug discovery. It offers a range of services including medicinal chemistry, computational chemistry, protein expression, assay development, and DMPK analysis. The company also focuses on developing treatments for inflammatory diseases like rheumatoid arthritis.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

IDM Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies aimed at destroying cancer cells and preventing tumor recurrence. The company's products work by activating the immune system or triggering a specific adaptive immune response, thereby enabling effective cancer control while prioritizing patient quality of life. IDM Pharma is committed to addressing the needs of both patients and the physicians who treat them, striving to maximize the therapeutic and commercial potential of its novel treatments.

Millennium Pharmaceuticals is a biopharmaceutical company focused on the research, development, and commercialization of cancer treatments. Established in 1993 and headquartered in Cambridge, Massachusetts, the company operates facilities in San Diego, San Francisco, Tsukuba, and Osaka. Millennium is known for developing VELCADE, an injectable therapy used for patients with multiple myeloma and relapsed mantle cell lymphoma. As of 2008, it has functioned as a subsidiary of Takeda Pharmaceutical Company, enhancing its capabilities and reach in the global market for oncology medications.

Takeda Bio Development Center Limited engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. Takeda Bio Development Center Ltd. was formerly known as Amgen Kabushiki Kaisha. As a result of the acquisition of Amgen Kabushiki Kaisha by Takeda Pharmaceutical Co., Amgen Kabushiki Kaisha's name was changed. As of April 1, 2008, Takeda Bio Development Center Ltd. operates as a subsidiary of Takeda Pharmaceutical Co. Ltd.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Xenon Pharmaceuticals is a biopharmaceutical company dedicated to developing novel medicines for neurological disorders. It focuses on rare genetic defects as drug targets, leveraging its proprietary discovery platform called Extreme Genetics. The company's pipeline includes XEN1101 and XEN496 for epilepsy treatment.

Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to developing first-in-class therapeutics targeting ion channels. Utilising proprietary proteomics technology, Lectus aims to create innovative treatments focused on pain management and urinary bladder disorders.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAbs), a novel biopharmaceutical class. The company focuses on creating treatments and prophylactics for severe human diseases, with a particular emphasis on cancer and infectious diseases. Their pipeline includes rpAb compositions for treating idiopathic thrombocytopenic purpura, preventing hemolytic disease in newborns, and mitigating adverse reactions from smallpox vaccinations, aiming to facilitate faster cancer treatment initiation and enhance overall treatment success.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.